- Home
- REGN vs WELL Comparison
REGN vs WELL Comparison
Compare REGN & WELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- WELL
- Stock Information
- Founded
- REGN 1988
- WELL 1970
- Country
- REGN United States
- WELL United States
- Employees
- REGN N/A
- WELL N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- WELL Real Estate Investment Trusts
- Sector
- REGN Health Care
- WELL Real Estate
- Exchange
- REGN Nasdaq
- WELL Nasdaq
- Market Cap
- REGN 63.4B
- WELL 94.9B
- IPO Year
- REGN 1991
- WELL N/A
- Fundamental
- Price
- REGN $547.67
- WELL $148.96
- Analyst Decision
- REGN Buy
- WELL Buy
- Analyst Count
- REGN 23
- WELL 11
- Target Price
- REGN $907.39
- WELL $158.09
- AVG Volume (30 Days)
- REGN 1.2M
- WELL 2.6M
- Earning Date
- REGN 04-29-2025
- WELL 04-28-2025
- Dividend Yield
- REGN 0.32%
- WELL 1.81%
- EPS Growth
- REGN 16.49
- WELL 111.52
- EPS
- REGN 39.43
- WELL 1.73
- Revenue
- REGN $14,085,700,000.00
- WELL $8,554,464,000.00
- Revenue This Year
- REGN $2.38
- WELL $23.39
- Revenue Next Year
- REGN $7.65
- WELL $12.01
- P/E Ratio
- REGN $14.23
- WELL $85.75
- Revenue Growth
- REGN 7.52
- WELL 24.49
- 52 Week Low
- REGN $520.50
- WELL $97.88
- 52 Week High
- REGN $1,211.20
- WELL $158.55
- Technical
- Relative Strength Index (RSI)
- REGN 38.69
- WELL 51.95
- Support Level
- REGN $542.44
- WELL $149.45
- Resistance Level
- REGN $615.61
- WELL $152.43
- Average True Range (ATR)
- REGN 22.06
- WELL 2.98
- MACD
- REGN -0.13
- WELL 0.29
- Stochastic Oscillator
- REGN 28.57
- WELL 63.64
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,271 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in both Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.